氨基酸转运载体SLC1A5在胃癌组织中的表达及其临床病理学意义

目的:研究氨基酸转运载体溶质载体家族1成员5(Solute Carrier Family 1 Member 5, SLC1A5)蛋白在胃癌组织中的表达情况,并探讨其与胃癌临床病理特征及预后的相关性。方法:收集进展期胃癌组织及对应癌旁组织90例,应用免疫组化技术检测SLC1A5在上述组织中的表达情况,并统计分析其表达与胃癌临床病理特征及预后的关系。同时通过基因数据库分析SLC1A5在胃癌组织和癌旁组织中表达情况及其对胃癌患者预后的影响。结果:与癌旁组织相比,胃癌组织中SLC1A5表达明显上调(P0.0001)。数据库研究也显示SLC1A5在胃癌组织中表达明显上调(GSE 65801,P=0.0046;GSE 63809,P0.0001;GSE 27342,P=0.0147)。胃癌组织中SLC1A5高表达与肿瘤大小(P0.05)、肿瘤浸润深度(P0.01)、淋巴结转移(P0.05)、TNM分期(P0.05)和Ki-67(P0.01)相关,而与年龄、性别、肿瘤位置及分化程度均无显著相关性(P0.05)。胃癌组织中SLC1A5表达强度与患者预后相关,表达越高,患者预后越差(总体生存率,P=0.0131;无复发生存率,P=0.0293)。数据库分析也显示SLC1A5高表达可明显缩短患者的总体生存期(GSE 14210,P=0.011;GSE 22377,P=0.0015)和无进展生存期(GSE 14210,P=0.0095;GSE 22377,P=0.0012)。结论:SLC1A5蛋白表达在胃癌组织中明显上调,且与肿瘤大小、肿瘤浸润深度、淋巴结转移及TNM分期有关。SLC1A5高表达与胃癌患者预后不良密切相关。

Expression of SLC1A5 in the Gastric Cancer and Its Correlation with the Clinicopathological Features of Gastric Cancer

ABSTRACT Objective: To detect the expression of Solute Carrier Family 1 Member 5(SLC1A5) in the gastric cancer (GC) and analyze its relationship with the clinicopathological features and prognosis and of GC patients. Methods: 90 cases of advanced GC tissue were selected as the experimental group, and corresponding paracancerous tissues were selected as the control group. Immunohistochemistry was used to detect the protein expression of SLC1A5 in 90 cases of advanced gastric cancer and its adjacent tissues. The relationship between the expression of SLC1A5 and clinicopathological features as well as the prognosis of GC patients was analyzed. By using gene database, we also analyzed the expression of SLC1A5 in GC tissues and adjacent tissues and its relationship with the prognosis of GC. Results: Compared to the control group, the expression of SLC1A5 was significantly increased in the advanced GC (P<0.0001). Statistical analysis by using GSE database also showed that the expression of SLC1A5 was significantly increased in the GC tissues compared to that of the paracancerous tissues (GSE 65801, P =0.0046; GSE 63809, P<0.0001; GSE 27342, P=0.0147). The expression of SLC1A5 in the GC tissue was correlated with the tumor size (P<0.05), depth of invasion (P<0.01), lymph node metastasis (P<0.05), TNM stage (P<0.05) and Ki-67 index (P<0.01). It had no significant correlation with the age, sex, tumor location and degree of differentiation. Overexpression of SLC1A5 in the GC tissue was associated with the poor prognosis (overall survival rate, P = 0.0131; non-recurrence survival rate, P = 0.0293). Meanwhile, database analysis also showed that higher expression level of SLC1A5 in GC was associated with the poor prognosis, which could significantly shorten the overall survival time (GSE 14210, P=0.011, GSE 22377, P=0.0015), and the progression free survival time of GC patients (GSE 14210, P=0.0095; GSE 22377, P=0.0012). Conclusion: SLC1A5 protein expression in the GC tissue was significantly upregulated, and it may be involved in the developement of advanced GC. High expression of SLC1A5 was associated with the poor prognosis of GC patients.